For as long as Medicare has existed, there's been one answer when clients asked us whether it would help pay for weight-loss medication: no. Federal law barred Medicare from covering drugs prescribed for weight loss, period. If your doctor prescribed Wegovy or Zepbound for obesity, you paid the full price — often $1,000 a month or more.

That changed on July 1, 2026.

A new federal program called the Medicare GLP-1 Bridge now lets eligible Medicare beneficiaries get certain weight-loss medications for about $50 a month. It's temporary, it has real eligibility requirements, and it doesn't cover every drug — but for the right person, it's one of the biggest changes to Medicare drug coverage in years.

Here's what our clients in Lexington, Columbia, and across the Midlands need to know.

What Is the GLP-1 Bridge Program?

GLP-1 medications — the family that includes Wegovy, Zepbound, and Ozempic — have been in the news for years because they work. But Medicare could only cover them when prescribed for something other than weight loss, like diabetes or reducing heart attack risk.

The GLP-1 Bridge is a temporary federal program, running from July 1, 2026 through December 31, 2027, that expands access for weight management specifically. Under the program, participating drug manufacturers agreed to supply certain GLP-1 medications at a sharply reduced price (around $245 a month), and eligible Medicare beneficiaries generally pay about $50 per monthly prescription.

It's called a "bridge" because it's designed to carry beneficiaries to a longer-term coverage approach Medicare is testing for 2027 and beyond.

Which Drugs Are Covered?

Not all of them — this catches a lot of people off guard. The Bridge program covers:

Wegovy (semaglutide) — both the injectable and the newer oral version. Zepbound (tirzepatide) — specifically the KwikPen. Foundayo — a new GLP-1 pill from Eli Lilly.

Notably absent: Ozempic. Ozempic is approved for diabetes, not weight loss, so it isn't part of this program — though Part D plans already cover it for diabetes, and it's also one of the drugs with new Medicare-negotiated prices as of January 2026.

Who Qualifies?

You must be enrolled in a Medicare Part D plan or a Medicare Advantage plan with drug coverage, and you must meet medical criteria. Broadly, there are two paths:

Path 1 — BMI of 30 or higher, plus a diagnosis such as heart failure, uncontrolled high blood pressure, or kidney disease.

Path 2 — BMI of 27 or higher, plus a history of stroke or heart attack, prediabetes, or peripheral artery disease.

Your doctor submits a prior authorization request to a central processing center and confirms you've received counseling on lifestyle changes — diet and exercise remain part of the treatment plan. This is not a program you sign up for at the pharmacy counter; it starts in your doctor's office.

What This Means in Real Dollars

If you've been paying cash for Wegovy in the Midlands, you know the sticker price can exceed $1,000 a month — over $12,000 a year. At roughly $50 a month, the same medication costs about $600 a year under the Bridge program.

One important note: because this is a special program with its own pricing, your Bridge copays work differently than your regular Part D spending. If you take other expensive medications and are tracking toward the $2,100 annual out-of-pocket cap (which we covered in our Part D changes guide), ask us how the two interact for your specific plan — this is exactly the kind of detail that varies and is worth a 15-minute phone call.

Common Questions We're Hearing

"I'm on Ozempic for diabetes. Does this change anything for me?" No — your coverage continues through your Part D plan as before. Good news anyway: Ozempic's Medicare-negotiated price took effect in January 2026, which is helping many plans' costs.

"My doctor mentioned Wegovy for my heart, not weight. Which coverage applies?" Wegovy prescribed to reduce cardiovascular risk was already coverable under Part D before this program. The Bridge specifically opens the door for weight management prescriptions. The path your doctor documents matters — and affects your cost.

"I'm turning 65 this year. Should this affect which plan I pick?" If a GLP-1 is part of your health picture, yes — plan selection matters more than ever, because you need a Part D or Medicare Advantage plan to access the Bridge at all, and plans differ on the rest of your medications. That's a conversation to have before you enroll, not after.

"Is this permanent?" No. It's scheduled through the end of 2027, with a broader coverage model being tested after that. Rules can change; that's the nature of a pilot program. We'll keep our clients posted.

The Bottom Line for Midlands Seniors

For years, weight-loss medication was simply off the table for Medicare beneficiaries unless they had another qualifying diagnosis. As of this month, there's a real, affordable path — if you meet the criteria and your paperwork is done right.

If you think you or your spouse might qualify, here's the simple next step: bring it up with your doctor, and then call us. We'll check how the Bridge program works with your current plan — or, if you're enrolling for the first time or reviewing during this fall's Annual Enrollment Period (October 15 – December 7), we'll factor it into which plan fits you best. As always, our help costs you nothing.

Call Jennifer at (843) 509-2462 or schedule your free Medicare review. We're right here in Lexington, and we've already helped neighbors from Lake Murray to Columbia sort this out.

Mauldin Insurance Group is an independent insurance agency in Lexington, SC. We do not offer every plan available in your area. Program details described are current as of July 2026 and subject to change; eligibility is determined through your provider and plan.